文献速递银屑病与炎症性皮肤病

Recibokibart(IL-36受体抗体)治疗泛发性脓疱型银屑病的2期随机试验

Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.
PubMed 文献 · Br J Dermatol · 2026-09-03

这项在中国开展的多中心、随机、双盲、安慰剂对照2期试验纳入33例中重度急性泛发性脓疱型银屑病(GPP)患者,按2:1随机接受单次静脉输注recibokibart 1050 mg或安慰剂。第1周(第8天)达到GPPGA脓疱子评分0或1的患者比例在recibokibart组为86.4%,安慰剂组为9.1%(组间差异77.3%,95%CI 42.5-88.9,P<0.0001)。单次给药后脓疱和整体皮肤病情快速改善,安全性可接受。

要点

  • 单次静脉输注recibokibart 1050 mg在第1周即显著提高GPPGA脓疱子评分0或1的患者比例。
  • recibokibart组第1周GPPGA总分0或1、脓疱完全清除及GPPASI较基线变化均优于安慰剂。
  • 临床改善最早在治疗后24小时出现,并维持至第12周(第8天后评估包含开放标签治疗患者)。

核心结论

  • 单次静脉输注recibokibart可使急性GPP发作患者的脓疱及整体皮肤病情严重度快速改善,且安全性可接受。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照2期试验,在中国开展,纳入33例中重度急性GPP患者。
  • 患者按2:1随机分配,第1天接受单次静脉输注recibokibart 1050 mg(n=22)或安慰剂(n=11)。
  • 第8天疾病活动持续者可接受开放标签recibokibart;达到GPPGA总分0或1后复发者可再接受一次开放标签剂量。
  • 主要疗效终点为第1周(第8天)达到GPPGA脓疱子评分0或1的患者比例。

主要发现

  • 第1周(第8天)达到GPPGA脓疱子评分0或1的患者比例:recibokibart组86.4% vs 安慰剂组9.1%(组间差异77.3%,95%CI 42.5-88.9,P<0.0001)。
  • 第1周(第8天)达到GPPGA总分0或1的患者比例:recibokibart组63.6% vs 安慰剂组0%。
  • 第1周(第8天)脓疱完全清除率:recibokibart组54.5% vs 安慰剂组0%。
  • 第1周(第8天)GPPASI较基线平均百分比变化:recibokibart组-59.3% vs 安慰剂组0%。
  • 第4周时recibokibart组72.7%的患者达到GPPASI 75;临床改善最早在治疗后24小时出现并维持至第12周。

关键数值与推荐

  • 主要终点:第1周(第8天)GPPGA脓疱子评分0或1的患者比例,recibokibart组86.4% vs 安慰剂组9.1%(P<0.0001)。
  • 第1周(第8天)GPPGA总分0或1:recibokibart组63.6% vs 安慰剂组0%。
  • 第1周(第8天)脓疱完全清除:recibokibart组54.5% vs 安慰剂组0%。
  • 第4周GPPASI 75:recibokibart组72.7%。

临床怎么用

  • 对于中重度急性GPP发作,单次静脉输注recibokibart 1050 mg可在第1周快速改善脓疱和整体皮肤病情。
  • 治疗前需评估基线GPPGA脓疱子评分、GPPGA总分及GPPASI,以便第1周和第4周评估疗效。
  • recibokibart最常见不良事件包括低蛋白血症、高甘油三酯血症、高脂血症和瘙痒。

局限性

  • 样本量较小,共33例患者随机分组(recibokibart组22例,安慰剂组11例)。
  • 第8天后的疗效评估包含接受开放标签治疗的患者,可能影响后续时间点结果的解释。
  • 研究仅在中国开展,结果外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Generalized pustular psoriasis (GPP) is a rare, severe inflammatory skin disease characterized by acute flares. Recibokibart is a humanized IgG1 monoclonal antibody targeting the interleukin-36 (IL-36) receptor. In a phase 1b open-label study, a single intravenous dose of recibokibart was associated with an acceptable safety profile and rapid improvements in pustulation, overall skin disease severity, and systemic inflammatory markers through 12 weeks. OBJECTIVES: This study aimed to evaluate the efficacy and safety of recibokibart in patients with acute flares of GPP. METHODS: In this multicenter, randomized, double-blind, placebo-controlled phase 2 trial conducted in China, patients with moderate-to-severe acute GPP were randomly assigned in a 2:1 ratio to receive a single intravenous dose of recibokibart (1050 mg) or placebo at day 1. Patients with persistent disease activity at day 8 were eligible to receive open-label recibokibart, and patients with recurrent flares after achieving a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score of 0 or 1 could receive an additional open-label dose. The primary efficacy endpoint was the proportion of patients who achieved a GPPGA pustulation sub-score of 0 or 1 at week 1 (day 8). RESULTS: A total of 33 patients were randomized (recibokibart, n=22; placebo, n=11). At week 1 (day 8), the primary endpoint of achieving a GPPGA pustulation sub-score of 0 or 1 was met by 86.4% of patients in the recibokibart group versus 9.1% in the placebo group (between-group difference, 77.3%; 95% CI, 42.5-88.9; P<0.0001). At week 1 (day 8), greater improvements were observed with recibokibart across key secondary endpoints, including achievement of a GPPGA total score of 0 or 1 (63.6% vs. 0%), complete pustule clearance (54.5% vs. 0%), and mean percentage change from baseline in GPPASI (-59.3% vs. 0%). By week 4, 72.7% of patients treated with recibokibart achieved GPPASI 75. Clinical improvements were observed as early as 24 hours after treatment and were maintained through week 12, although assessments after day 8 included patients who received open-label treatment. The most frequently reported adverse events with recibokibart included hypoproteinemia, hypertriglyceridemia, hyperlipidemia, and pruritus. CONCLUSIONS: A single intravenous dose of recibokibart resulted in rapid improvement in pustular and overall skin disease severity in patients with acute GPP flares, with an acceptable safety profile.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Yang B, Li Y, Wang Y, et al. Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial. Br J Dermatol. 2026. PMID: 42687756. doi:10.1093/bjd/ljag369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。